2025-2029年全球製药业机器学习展望

全球製药业机器学习市场预计将以 37.1% 的复合年增长率成长，在 2024 年至 2029 年的预测期内达到 102.128 亿美元。本报告对全球製药业机器学习市场进行了全面分析，包括市场规模和预测、趋势、成长要素和挑战，以及对约 25 家公司的供应商分析。

本报告提供对当前市场格局、最新趋势和驱动因素以及整体市场环境的最新分析。市场成长的驱动因素包括数据量和复杂性的增加、对提高效率和降低成本的需求，以及个人化和精准医疗的发展。

本研究采用客观的方法，结合一手和二手讯息，包括来自主要行业相关人员的意见。报告包含对主要企业的分析、全面的市场规模数据、区域細項分析以及供应商格局。报告提供历史数据和预测数据。

研究指出，生成式人工智慧在新药研发领域的兴起是未来几年推动全球製药业机器学习市场成长的主要因素之一。此外，联邦学习在资料隐私保护方面的日益普及，以及人工智慧与数位生物标记和穿戴式技术的日益融合，预计也将为市场带来巨大的需求。

目录

第一章执行摘要

第二章 Technavio 分析

• 价格、生命週期、顾客购买篮、采用率和购买标准分析
• 投入与差异化因素的重要性
• 混淆来源
• 驱动因素和挑战的影响

第三章 市场情势

• 市场生态系统
• 市场特征
• 价值链分析

第四章 市场规模

• 市场定义
• 市场区隔分析
• 2024年市场规模
• 2024-2029年市场展望

第五章 市场规模表现

• 2019-2023年全球製药业机器学习市场
• 应用细分市场分析 2019-2023
• 2019-2023年技术细分市场分析
• 2019-2023年部署细分市场分析
• 2019-2023年区域细分市场分析
• 2019-2023年国家细分市场分析

第六章五力分析

• 五力分析概述
• 买方的议价能力
• 供应商的议价能力
• 新进入者的威胁
• 替代品的威胁
• 竞争威胁
• 市场状况

第七章 按应用程式进行市场区隔

• 比较：透过应用
• 药物发现与设计
• 临床试验优化
• 疾病诊断和生物标记鑑定
• 生产製造和品管
• 其他的
• 按应用分類的市场机会

8. 按技术分類的市场细分

• 比较：按技术
• 监督式学习
• 深度学习
• 无监督学习
• 强化学习
• 其他的
• 按技术分類的市场机会

9. 依部署方式进行市场区隔

• 比较：依部署方式
• 基于云端的
• 杂交种
• 本地部署
• 按部署方式分類的市场机会

第十章 客户情况

第十一章 区域情势

• 区域细分
• 区域比较
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 印尼
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 荷兰
  • 西班牙
• 南美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非
  • 以色列
  • 土耳其
• 各区域的市场机会

第十二章：驱动因素、挑战与机会

• 市场驱动因素
• 市场挑战
• 驱动因素和挑战的影响
• 市场机会

第十三章 竞争格局

• 概述
• 竞争格局
• 令人困惑的局面
• 产业风险

第十四章 竞争分析

• 公司简介
• 企业排名指数
• 公司市场定位
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• IQVIA Holdings Inc.
• Johnson and Johnson Services
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Ltd.

第十五章附录

The global machine learning in pharmaceutical industry market is forecasted to grow by USD 10212.8 mn during 2024-2029, accelerating at a CAGR of 37.1% during the forecast period. The report on the global machine learning in pharmaceutical industry market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing data volume and complexity, quest for enhanced efficiency and reduced costs, personalized medicine and precision therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global machine learning in pharmaceutical industry market is segmented as below:

By Application

• Drug discovery and design
• Clinical trial optimization
• Disease diagnosis and biomarker identification
• Manufacturing and quality control
• Others

By Technology

• Supervised learning
• Deep learning
• Unsupervised learning
• Reinforcement learning
• Others

By Deployment

• Cloud-based
• Hybrid
• On premises

Geography

• North America
  • US
  • Canada
  • Mexico
• APAC
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
• Europe
  • Germany
  • UK
  • France
  • Italy
  • The Netherlands
  • Spain
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • UAE
  • South Africa
  • Turkey
• Rest of World (ROW)

This study identifies the rise of generative AI for de novo drug design as one of the prime reasons driving the global machine learning in pharmaceutical industry market growth during the next few years. Also, increasing adoption of federated learning for data privacy and integration of AI with digital biomarkers and wearable technology will lead to sizable demand in the market.

The report on the global machine learning in pharmaceutical industry market covers the following areas:

• Global machine learning in pharmaceutical industry market sizing
• Global machine learning in pharmaceutical industry market forecast
• Global machine learning in pharmaceutical industry market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global machine learning in pharmaceutical industry market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Atomwise Inc., Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ICON plc, Insilico Medicine, IQVIA Holdings Inc., Johnson and Johnson Services, Merck and Co. Inc., Novartis AG, Pfizer Inc., Recursion Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Ltd.. Also, the global machine learning in pharmaceutical industry market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Market Segmentation by Deployment
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Machine Learning In Pharmaceutical Industry Market 2019 - 2023
  • Historic Market Size - Data Table on Global Machine Learning In Pharmaceutical Industry Market 2019 - 2023 ($ million)
• 5.2 Application segment analysis 2019 - 2023
  • Historic Market Size - Application Segment 2019 - 2023 ($ million)
• 5.3 Technology segment analysis 2019 - 2023
  • Historic Market Size - Technology Segment 2019 - 2023 ($ million)
• 5.4 Deployment segment analysis 2019 - 2023
  • Historic Market Size - Deployment Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Five Forces Analysis

• 6.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 6.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 6.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 6.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 6.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 6.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 6.7 Market condition

7 Market Segmentation by Application

• 7.1 Market segments
• 7.2 Comparison by Application
• 7.3 Drug discovery and design - Market size and forecast 2024-2029
• 7.4 Clinical trial optimization - Market size and forecast 2024-2029
• 7.5 Disease diagnosis and biomarker identification - Market size and forecast 2024-2029
• 7.6 Manufacturing and quality control - Market size and forecast 2024-2029
• 7.7 Others - Market size and forecast 2024-2029
• 7.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

8 Market Segmentation by Technology

• 8.1 Market segments
• 8.2 Comparison by Technology
• 8.3 Supervised learning - Market size and forecast 2024-2029
• 8.4 Deep learning - Market size and forecast 2024-2029
• 8.5 Unsupervised learning - Market size and forecast 2024-2029
• 8.6 Reinforcement learning - Market size and forecast 2024-2029
• 8.7 Others - Market size and forecast 2024-2029
• 8.8 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

9 Market Segmentation by Deployment

• 9.1 Market segments
• 9.2 Comparison by Deployment
• 9.3 Cloud-based - Market size and forecast 2024-2029
• 9.4 Hybrid - Market size and forecast 2024-2029
• 9.5 On premises - Market size and forecast 2024-2029
• 9.6 Market opportunity by Deployment
  • Market opportunity by Deployment ($ million)

10 Customer Landscape

• 10.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

11 Geographic Landscape

• 11.1 Geographic segmentation
• 11.2 Geographic comparison
• 11.3 North America - Market size and forecast 2024-2029
  • 11.3.1 US - Market size and forecast 2024-2029
  • 11.3.2 Canada - Market size and forecast 2024-2029
  • 11.3.3 Mexico - Market size and forecast 2024-2029
• 11.4 APAC - Market size and forecast 2024-2029
  • 11.4.1 China - Market size and forecast 2024-2029
  • 11.4.2 India - Market size and forecast 2024-2029
  • 11.4.3 Japan - Market size and forecast 2024-2029
  • 11.4.4 South Korea - Market size and forecast 2024-2029
  • 11.4.5 Australia - Market size and forecast 2024-2029
  • 11.4.6 Indonesia - Market size and forecast 2024-2029
• 11.5 Europe - Market size and forecast 2024-2029
  • 11.5.1 Germany - Market size and forecast 2024-2029
  • 11.5.2 UK - Market size and forecast 2024-2029
  • 11.5.3 France - Market size and forecast 2024-2029
  • 11.5.4 Italy - Market size and forecast 2024-2029
  • 11.5.5 The Netherlands - Market size and forecast 2024-2029
  • 11.5.6 Spain - Market size and forecast 2024-2029
• 11.6 South America - Market size and forecast 2024-2029
  • 11.6.1 Brazil - Market size and forecast 2024-2029
  • 11.6.2 Argentina - Market size and forecast 2024-2029
  • 11.6.3 Colombia - Market size and forecast 2024-2029
• 11.7 Middle East and Africa - Market size and forecast 2024-2029
  • 11.7.1 Saudi Arabia - Market size and forecast 2024-2029
  • 11.7.2 UAE - Market size and forecast 2024-2029
  • 11.7.3 South Africa - Market size and forecast 2024-2029
  • 11.7.4 Israel - Market size and forecast 2024-2029
  • 11.7.5 Turkey - Market size and forecast 2024-2029
• 11.8 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

12 Drivers, Challenges, and Opportunity

• 12.1 Market drivers
  • Increasing data volume and complexity
  • Quest for enhanced efficiency and reduced costs
  • Personalized medicine and precision therapies
• 12.2 Market challenges
  • Data silos and interoperability issues
  • Regulatory and ethical considerations
  • Talent gap and skill shortages
• 12.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 12.4 Market opportunities
  • Rise of generative AI for de novo drug design
  • Increasing adoption of federated learning for data privacy
  • Integration of AI with digital biomarkers and wearable technology

13 Competitive Landscape

• 13.1 Overview
• 13.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 13.3 Landscape disruption
  • Overview on factors of disruption
• 13.4 Industry risks
  • Impact of key risks on business

14 Competitive Analysis

• 14.1 Companies profiled
  • Companies covered
• 14.2 Company ranking index
  • Company ranking index
• 14.3 Market positioning of companies
  • Matrix on companies position and classification
• 14.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 14.5 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT
• 14.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 14.7 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 14.8 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 14.9 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 14.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 14.11 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 14.12 IQVIA Holdings Inc.
  • IQVIA Holdings Inc. - Overview
  • IQVIA Holdings Inc. - Business segments
  • IQVIA Holdings Inc. - Key offerings
  • IQVIA Holdings Inc. - Segment focus
  • SWOT
• 14.13 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 14.14 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 14.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 14.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT
• 14.17 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 14.18 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Product / Service
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • SWOT

15 Appendix

• 15.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 15.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 15.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 15.4 Research methodology
  • Research methodology
• 15.5 Data procurement
  • Information sources
• 15.6 Data validation
  • Data validation
• 15.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 15.8 Data synthesis
  • Data synthesis
• 15.9 360 degree market analysis
  • 360 degree market analysis
• 15.10 List of abbreviations
  • List of abbreviations